Biogen Inc (BIIB)

BIIB (NASDAQ:Drugs) EQUITY
$392.88
pos +0.00
+0.00%
Today's Range: 0.00 - 0.00 | BIIB Avg Daily Volume: 1,965,500
Last Update: 05/26/15 - 3:59 PM EDT
Volume: 0
YTD Performance: 15.74%
Open: $0.00
Previous Close: $392.88
52 Week Range: $290.85 - $480.18
Oustanding Shares: 235,229,512
Market Cap: 93,781,301,844
6-Month Chart
TheStreet Ratings Grade for BIIB
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 9 11 9 12
Moderate Buy 2 2 1 1
Hold 6 3 5 4
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 1.79 1.47 1.73 1.53
Latest Dividend: 0.00
Latest Dividend Yield: 0.00%
Dividend Ex-Date: 12/31/69
Price Earnings Ratio: 28.81
Price Earnings Comparisons:
BIIB Sector Avg. S&P 500
28.81 28.80 27.04
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
-4.20% 31.09% 198.63%
GROWTH 12 Mo 3 Yr CAGR
Revenue 46.50 0.92 0.24
Net Income 57.90 1.32 0.32
EPS 58.30 1.44 0.34
Earnings for BIIB:
EBITDA 3.41B
Revenue 8.51B
Average Earnings Estimates
Qtr (06/15) Qtr (09/15) FY (12/15) FY (12/16)
Average Estimate $4.08 $4.31 $16.70 $19.55
Number of Analysts 11 11 12 12
High Estimate $4.26 $4.41 $16.96 $20.41
Low Estimate $3.99 $4.21 $16.46 $18.32
Prior Year $3.49 $3.79 $13.79 $16.70
Growth Rate (Year over Year) 17.04% 13.74% 21.13% 17.02%
Chart Benchmark Timeframe
Average Frequency Indicator Chart
Scale Symbol Comparison Bollinger Bands
By

Jim Cramer

 | May 21, 2015 | 12:21 PM EDT

Jim Cramer answers viewers' Twitter (TWTR) questions from the floor of the New York Stock Exchange.

By

Jim Cramer

 | May 18, 2015 | 12:19 PM EDT

Many of these stocks are off to the races.

By

Jim Cramer

 | May 13, 2015 | 11:17 AM EDT

Jim Cramer answers viewers' stock questions from the floor of the New York Stock Exchange.

By

Jim Cramer

 | May 6, 2015 | 1:33 PM EDT

It's not the Fed chief's place.

By

Jim Cramer

 | May 4, 2015 | 11:51 AM EDT

And it's not the favorable macroeconomic climate.

By

Jim Cramer

 | Apr 24, 2015 | 11:22 AM EDT

Biogen miss no reason to abandon big 4 of Big Pharma.

By

David Peltier

 | Apr 23, 2015 | 4:44 PM EDT

Telecom, utility and energy names led the way higher Thursday.

By

Robert Lang

 | Apr 22, 2015 | 10:52 AM EDT

Gilead's Relative Strength Index slope is very strong.

By

Robert Lang

 | Apr 22, 2015 | 10:00 AM EDT

Gilead's Relative Strength Index slope is very strong.

By

Jim Cramer

 | Apr 8, 2015 | 3:46 PM EDT

Even the second-tier biotechs are taking off.

Dude made it sound like any sniff of positive data in the next two weeks has him ready to ...
1. As promised I am delivering a summary of some of the regional banks I own in my opening...
Europe was the top destination for foreign direct investment, with Western Europe apparent...
The IRS said that identity thieves had accessed about 100,000 U.S. households' tax records...

REAL MONEY PRO'S BEST IDEAS

Columnist Tweets

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.